Theranexus (EPA:ALTHX)

BRIEF

published on 11/07/2025 at 18:05, 10 months 5 days ago

Theranexus: Publication of voting rights and shares as of October 31, 2025

Share Capital Voting Rights Biopharmaceutical Rare Diseases Theranexus
PRESS RELEASE

published on 10/23/2025 at 08:00, 10 months 21 days ago

THX Pharma announces the launch of a capital increase with preferential subscription rights of nearly EUR 8 million
THX Pharma launches a €8 million capital increase to fund rare neurological drug development, with 75.5% commitments secured. Batten-1 and TX01 to lead clinical and commercial endeavors with strategic shift to international markets. Investment opportunities for various tax schemes

Investment Capital Increase Drug Development Neurological Diseases THX Pharma
BRIEF

published on 10/14/2025 at 18:35, 10 months 29 days ago

THX Pharma and Exeltis Advance Toward Commercialization of TX01

Marketing Rare Diseases Exeltis TX01 THX Pharma
PRESS RELEASE

published on 10/14/2025 at 18:30, 10 months 29 days ago

THX PHARMA (THERANEXUS) AND EXELTIS ACHIEVE KEY MILESTONE TOWARDS THE COMMERCIALIZATION OF TX01
THX Pharma (Theranexus) and Exeltis achieve key milestone towards the commercialization of TX01 for rare neurological diseases, including Gaucher and Niemann-Pick type C. A pivotal step towards regulatory submission and global launch

Commercialization Neurological Diseases Exeltis TX01 THX Pharma
BRIEF

published on 09/29/2025 at 18:35, 11 months 13 days ago

THX Pharma: a strategic evolution towards international expansion

Growth Strategy Rare Diseases THX Pharma International Marketing Drugs TX01 And Batten-1
PRESS RELEASE

published on 09/29/2025 at 18:30, 11 months 13 days ago

Theranexus Becomes THX Pharma: A Strategic Evolution Toward the Commercialization of Its Medicines for Rare Diseases
THX Pharma (formerly Theranexus) announces strategic focus on regulatory approval, early access, and global commercialization of new drug candidates for rare neurological diseases

Regulatory Approval Commercialization Rare Neurological Diseases THX Pharma Early Access
BRIEF

published on 09/25/2025 at 18:05, 11 months 17 days ago

Theranexus publishes its financial results for the first half of 2025

Financial Results Cost Reduction Theranexus Batten-1 TX01
PRESS RELEASE

published on 09/25/2025 at 18:00, 11 months 17 days ago

THERANEXUS ANNOUNCES FIRST HALF 2025 FINANCIAL RESULTS
Theranexus announces first half 2025 financial results showing a decrease in operating expenses and a net loss of €1,072 K. Focus on developing flagship asset TX01 and advancing Batten-1

Financial Results Theranexus Batten-1 Operating Expenses TX01
BRIEF

published on 07/17/2025 at 18:05, 1 year 1 month ago

Half-Yearly Review of the Theranexus Liquidity Contract

Liquidity Contract PORTZAMPARC Financial Statement Biopharmaceuticals Theranexus
BRIEF

published on 07/10/2025 at 18:05, 1 year 2 months ago

Theranexus Reveals its Cash Position as of June 30, 2025

Treasury Biopharmaceutical Innovation Theranexus Batten-1 Neurological Diseases

Published on 09/12/2026 at 02:35, 1 day 9 hours ago

Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 1 day 12 hours ago

Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 1 day 13 hours ago

Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 1 day 14 hours ago

Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 1 day 18 hours ago

Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors

View all ACCESSWIRE

Published on 09/12/2026 at 17:50, 17 hours 49 minutes ago

New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Published on 09/12/2026 at 07:30, 1 day 4 hours ago

NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 1 day 13 hours ago

Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 1 day 13 hours ago

Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 1 day 15 hours ago

DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031

View all EQS

Published on 09/11/2026 at 07:00, 2 days 4 hours ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 2 days 4 hours ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/10/2026 at 19:30, 2 days 16 hours ago

Availability of the 2026 Interim Financial Report
Published on 09/10/2026 at 07:00, 3 days 4 hours ago

2026 H1 results and new identity
Published on 09/09/2026 at 18:45, 3 days 16 hours ago

Successful launch of a €500 million bond issue

View all LES ECHOS COMFI WIRE

News